These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 15161337)

  • 1. Etanercept: in ankylosing spondylitis.
    McCormack PL; Wellington K
    BioDrugs; 2004; 18(3):199-205; discussion 206. PubMed ID: 15161337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.
    Gorman JD; Sack KE; Davis JC
    N Engl J Med; 2002 May; 346(18):1349-56. PubMed ID: 11986408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A multicenter, double-blind, randomized, placebo-controlled clinical trial of etanercept treatment of Chinese patients with active ankylosing spondylitis].
    Huang F; Zhang J; Zheng Y; Xu JH; Li XF; Wu HX; Chen ZW; Zhao Z; Zhang YM
    Zhonghua Nei Ke Za Zhi; 2011 Dec; 50(12):1043-7. PubMed ID: 22333175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.
    Davis JC; Van Der Heijde D; Braun J; Dougados M; Cush J; Clegg DO; Kivitz A; Fleischmann R; Inman R; Tsuji W;
    Arthritis Rheum; 2003 Nov; 48(11):3230-6. PubMed ID: 14613288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A multicenter, double-blind, placebo-controlled, randomized, phase III clinical study of etanercept in treatment of ankylosing spondylitis].
    Huang F; Zhang J; Huang JL; Wu DH; Li ZG; Chen SL; Pan YF; Ma L; Chen S; Lü LJ; Yang ZM
    Zhonghua Nei Ke Za Zhi; 2010 Sep; 49(9):741-5. PubMed ID: 21092442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis.
    Calin A; Dijkmans BA; Emery P; Hakala M; Kalden J; Leirisalo-Repo M; Mola EM; Salvarani C; Sanmartí R; Sany J; Sibilia J; Sieper J; van der Linden S; Veys E; Appel AM; Fatenejad S
    Ann Rheum Dis; 2004 Dec; 63(12):1594-600. PubMed ID: 15345498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis.
    Brandt J; Listing J; Haibel H; Sörensen H; Schwebig A; Rudwaleit M; Sieper J; Braun J
    Rheumatology (Oxford); 2005 Mar; 44(3):342-8. PubMed ID: 15561737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis.
    van der Heijde D; Da Silva JC; Dougados M; Geher P; van der Horst-Bruinsma I; Juanola X; Olivieri I; Raeman F; Settas L; Sieper J; Szechinski J; Walker D; Boussuge MP; Wajdula JS; Paolozzi L; Fatenejad S;
    Ann Rheum Dis; 2006 Dec; 65(12):1572-7. PubMed ID: 16968715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Anti-TNF alfa therapy in ankylosing spondylitis].
    Cravo AR; Tavares V; Da Silva JC
    Acta Med Port; 2006; 19(2):141-50. PubMed ID: 17187716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis.
    Culy CR; Keating GM
    Drugs; 2002; 62(17):2493-537. PubMed ID: 12421111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks.
    Davis JC; van der Heijde DM; Braun J; Dougados M; Cush J; Clegg D; Inman RD; Kivitz A; Zhou L; Solinger A; Tsuji W
    Ann Rheum Dis; 2005 Nov; 64(11):1557-62. PubMed ID: 15843448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etanercept: a review of its use in rheumatoid arthritis.
    Jarvis B; Faulds D
    Drugs; 1999 Jun; 57(6):945-66. PubMed ID: 10400407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.
    Brandt J; Khariouzov A; Listing J; Haibel H; Sörensen H; Grassnickel L; Rudwaleit M; Sieper J; Braun J
    Arthritis Rheum; 2003 Jun; 48(6):1667-75. PubMed ID: 12794835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis.
    Davis JC; van der Heijde DM; Braun J; Dougados M; Clegg DO; Kivitz AJ; Fleischmann RM; Inman RD; Ni L; Lin SL; Tsuji WH
    Ann Rheum Dis; 2008 Mar; 67(3):346-52. PubMed ID: 17967833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study.
    Dougados M; Wood E; Combe B; Schaeverbeke T; Miceli-Richard C; Berenbaum F; Koppiker N; Dubanchet A; Logeart I
    Arthritis Res Ther; 2014 Nov; 16(6):481. PubMed ID: 25428762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly.
    Braun J; McHugh N; Singh A; Wajdula JS; Sato R
    Rheumatology (Oxford); 2007 Jun; 46(6):999-1004. PubMed ID: 17389658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etanercept: a review of its use in the management of ankylosing spondylitis and psoriatic arthritis.
    Hoy SM; Scott LJ
    Drugs; 2007; 67(17):2609-33. PubMed ID: 18034593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Etanercept in adult patients with early onset ankylosing spondylitis.
    Inman RD; Clegg DO; Davis JC; Whitmore JB; Solinger A
    J Rheumatol; 2006 Aug; 33(8):1634-6. PubMed ID: 16881118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Etanercept: new indication. For ankylosing spondylitis: another option.
    Prescrire Int; 2005 Jun; 14(77):92-3. PubMed ID: 15981387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spotlight on etanercept in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis.
    Culy CR; Keating GM
    BioDrugs; 2003; 17(2):139-45. PubMed ID: 12641492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.